Needham analyst Gil Blum maintained a Buy rating on Gamida Cell (GMDA - Research Report) today and set a price target of $12.00. The company's shares opened today at $3.07.According to TipRanks, Blum is an analyst with an average return of -2.3% and a 44.85% success rate. Blum covers the Healthcare sector, focusing on stocks such as Sarepta Therapeutics, CTI BioPharma, and Crispr Therapeutics AG.Gamida Cell has an analyst consensus of Strong Buy, with a price target consensus of $14.80, implying a 382.08% upside from current levels. In a report released today, Piper Sandler also maintained a Buy rating on the stock with a $8.00 price target.
https://www.tipranks.com/news/blurbs/needham-reaffirms-their-buy-rating-on-gamida-cell-gmda?utm_source=advfn.com&utm_medium=referral